Recently, lysergic acid diethylamide (LSD) has become a resurgent drug of abuse. The detection of LSD is problematic because of the low dosage taken by users, light and heat sensitivity of the analyte, and the lack of efficient analytical methods. Presented here is the validation of an automated sample preparation method for the analysis of LSD and its primary urinary metabolite, 2-oxo-3-hydroxy-LSD (OHLSD), in urine samples by liquid chromatography-tandem mass spectrometry (LC–MS-MS). Analytes were extracted from urine using an automated Dispersive Pipette XTRaction (DPX) method on Hamilton STAR and STARlet liquid handling systems. The limit of detection for both analytes was administratively defined at the lowest calibrator used in the experiments, and the limit of quantitation was 0.05 ng/mL for both analytes. All validation criteria were acceptable per Department of Defense Instruction 1010.16 requirements. This method offers an efficient, sensitive analytical solution to routinely evaluate large numbers of urine specimens for LSD in workplace drug-deterrence programs.

中文翻译：

---

通过自动萃取和液相色谱-串联质谱法定量分析尿液中的麦角酸二乙胺 (LSD) 和 2-oxo-3-hydroxy-LSD

最近，麦角酰二乙胺（LSD）已成为一种死灰复燃的滥用药物。LSD 的检测存在问题，因为使用者服用的剂量低，分析物对光和热敏感，并且缺乏有效的分析方法。这里介绍的是通过液相色谱-串联质谱法（LC–MS-多发性硬化症）。在 Hamilton STAR 和 STARlet 液体处理系统上使用自动分散移液器 XTRaction (DPX) 方法从尿液中提取分析物。两种分析物的检测限均按实验中使用的最低校准品进行管理定义，两种分析物的定量限均为 0.05 ng/mL。根据国防部指令 1010.16 的要求，所有验证标准都是可接受的。这种方法提供了一种高效、灵敏的分析解决方案，可在工作场所药物威慑计划中常规评估大量尿液样本中的 LSD。